key: cord-0023233-l8sz39rf
authors: Mahmood, Tahir; Shapiro, Michael D.
title: The Questions on Everyone’s Mind: What is and Why Do We Need Preventive Cardiology?
date: 2021-09-24
journal: nan
DOI: 10.14797/mdcvj.698
sha: 6f2eba6619784e9c19d929d761df2f2686ed54bc
doc_id: 23233
cord_uid: l8sz39rf

Despite being largely preventable, atherosclerotic cardiovascular disease (ASCVD) continues to be the leading source of morbidity and mortality worldwide. While the past few decades have seen a substantial reduction in ASCVD mortality, much of this is due to significant improvements in treatment of already manifest disease, with its attendant morbidity and impact on quality of life. Moreover, evidence now suggests that ASCVD mortality in the United States has hit a nadir and is likely to start increasing again. It is now time to shift our attention from intervention to prevention. In this review, we explore the tremendous opportunity to define and implement the discipline of preventive cardiology.

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of both morbidity and mortality worldwide. In 2019 alone, there were roughly 523.2 million cases and 18.6 million deaths attributed to cardiovascular disease globally. 1 The financial burden of CVD is equally enormous, with direct costs exceeding $200 billion annually in the United States alone. 1 While there is certain age-related risk, the fact that ASCVD is largely preventable makes these numbers rather astonishing to consider.

The overarching strategies for primary ASCVD prevention are seemingly intuitive-maintaining a healthy diet and normal weight, engaging in regular exercise, tobacco cessation, and regular monitoring of blood pressure, cholesterol, and blood sugar. 2 However, actual implementation and monitoring of these preventive strategies in medical practice has been oversimplified and suboptimal. 3 Prime examples include the vast underdiagnosis of obesity and familial hypercholesterolemia in primary care throughout the world. [4] [5] [6] [7] Our limited effectiveness in preventing ASCVD coupled by its immense burden have driven recent efforts to establish a dedicated preventive cardiology subspecialty. 8 In this review, we contextualize the need for preventive cardiology and highlight emerging ideas within the developing field.

ASCVD mortality in the United States has substantially reduced over the past four decades, 1 but this comes with two notable caveats. First, about half of these reductions have been attributed to improvements in the care and treatment of already established ASCVD. 9 We experienced significant breakthroughs in systems of care, including advances in surgical and interventional techniques, decreased door to balloon time in STelevation myocardial infarctions, development of cardiac care units, and use of novel medications for secondary prevention. Nonetheless, these innovations allow patients to live longer with significant morbidity, and many can experience remarkable reductions in quality of life. For example, a recent study found that older adults with CVD have higher rates of rapid functional decline compared to those without (23.8% vs 16.2%). 10 Of course, a more prudent strategy would be to focus more of our energies on preventing ASCVD in the first place.

The second and perhaps more alarming caveat is that reductions in ASCVD mortality appear to be hitting a nadir in the United States. Evidence suggests that the rate of ASCVD mortality decline has significantly slowed in many high-income countries. In fact, ASCVD mortality appears to actually be rising in US adults aged 35 to 74 years. 11 The most obvious reason for this is the high and increasing levels of obesity and diabetes, which remain growing universal epidemics. 12 Smoking prevalence is also low enough in the United States that further declines are having a relatively smaller impact on mortality. Lastly, it is important to keep in mind that persistent inequities exist in ASCVD risk, many of which are grounded in socioeconomic disparities. 13 Together, these factors pose significant challenges to public policymakers to promote better cardiovascular health, and they certainly play a role in the stagnating ASCVD mortality trends in the United States.

It would be remiss to ignore the intersection between ASCVD and the ongoing COVID-19 pandemic. 14 A recent large meta-analysis demonstrated that ASCVD and its risk factors are associated with increased mortality from COVID-19 infection across all age groups. 15 Accordingly, the Centers for Disease Control and Prevention currently lists heart conditions (including coronary artery disease), obesity, smoking, and type 2 diabetes mellitus among conditions that increase risk for severe illness from COVID-19. 16 The COVID-19 pandemic not only emphasizes the unfortunate pervasiveness of ASCVD comorbidity throughout the medical system but also underscores the need for a more comprehensive and dedicated approach to ASCVD prevention overall, especially to help control future public health crises. 17

Paradigms surrounding ASCVD prevention have undergone multiple shifts within the past century. The early stages of ASCVD prevention can be traced back to 1948 with the initiation of the Framingham Heart Study. 18 It was within this landmark epidemiological study that traditional modifiable risk factors associated with ASCVD-including hypercholesterolemia, hypertension, diabetes, and smoking-were first identified and popularized. 19 Ultimately, identification of these risk factors helped to establish the well-known Framingham Risk Score 20 and have formed the basis of modern 10year quantitative risk assessment in primary prevention. 21 Ensuing clinical trials evaluated lifestyle modifications and medications to control these risk factors, and early evidence suggested that these strategies were effective in modifying risk. [22] [23] [24] The real revolution, however, arrived with the 1994 report from the first of the statin megatrials, the Scandinavian Simvastatin Survival Study, which demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) in secondary prevention reduced recurrent atherosclerotic event rates and ASCVD mortality. 25 This ushered in the second wave of preventive cardiology. Subsequent randomized placebo-controlled statin trials demonstrated remarkably consistent results in essentially all patient groups. At this point, cholesterol management became central to the mission of ASCVD prevention. 26 However, while evaluation and management of LDL-C remains a critically important aspect of CVD prevention, contemporary (ie, the third wave) preventive cardiology embraces the notion that LDL-C is only one component of a larger, more comprehensive evaluation and management strategy to mitigate ASCVD risk.

Until recently, prevention of ASCVD has centered around LDL-C prevention. Although this strategy has paid great dividends, it is well known that risk reduction with statins is incomplete. In fact, the recently-dubbed term "residual cardiovascular risk" refers to the fact that significant risk of cardiovascular events remains despite optimal statin therapy. The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) examined whether the addition of ezetimibe to statin therapy could reduce rates of recurrent cardiovascular events in patients with recent acute coronary syndrome. 27 Despite incrementally decreasing LDL-C levels by more than 20% and reducing cardiovascular event rates by 2% compared with the simvastatin monotherapy group, significant cumulative rates of recurrent cardiovascular events remained in the simvastatin-ezetimibe group after 7-year follow-up (32.7%).

The cardiovascular outcome trials evaluating the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer the most poignant example of residual risk and the need to address all risk factors. [28] [29] [30] In the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk) trial, the PCSK9 inhibitor evolocumab was shown to incrementally improve cardiovascular outcomes in patients with stable ASCVD on background high-intensity statin therapy. 29 However, despite achieving median LDL-C levels of 30 mg/dL with evolocumab, recurrent cardiovascular event rates (ie, residual risk) remained high (12.6% cumulative incidence of cardiovascular events at 3 years). Furthermore, a prespecified secondary analysis of the FOURIER trial demonstrated that while evolocumab could safely achieve single digit LDL-C concentrations, essentially eliminating LDL-C from the ASCVD risk equation, patients remained at relatively high risk. 31 As such, while we are fortunate to have effective tools to dramatically lower LDL-C, the time has come to move beyond LDL-C and consider all of the categories of residual ASCVD risk (Figure 1) . 32 Fortunately, we find ourselves in a therapeutic renaissance that has the potential to dramatically attenuate ASCVD risk. 

In the past, the medical community had little to offer in terms of ASCVD risk assessment and management. Traditional quantitative risk assessment tools performed modestly, and management of ASCVD risk had been relatively narrow and nonspecific. We now have more precise methods to identify individuals who will most likely benefit from therapy and to tailor individualized therapeutic interventions. Significant advances have been made in subclinical atherosclerosis imaging, including coronary artery calcium scoring, coronary computed tomography angiography, and carotid artery ultrasound for intima-media thickness and plaque. Evaluation of multiple novel and promising biomarkers for ASCVD are underway. 33 Genetic testing, whether through assessment of one or thousands of alterations in the genome, is gaining traction. In particular, there has been abundant interest in polygenic risk scores, 34, 35 which may be in clinical practice relatively soon. Additionally, there are a multitude of emerging therapeutics ( Table 1) 36 that address lipids, diabetes, weight, blood pressure, thrombosis, and inflammation by leveraging novel modalities such as monoclonal antibodies, antisense nucleotides, silencing ribonucleic acids, CRISPR-based techniques (clustered regularly interspaced short palindromic repeats), and vaccines. Moreover, the future of preventive cardiology should not be limited to prevention of atherosclerotic events but should expand to include prevention of heart failure and atrial fibrillation. 37, 38 Prevention of cognitive decline is another intriguing area of interest given the shared risk factor profile between dementia and ASCVD.

Given the burden, trends, and multidimensional nature of ASCVD, there has never been a greater need and opportunity for the creation of a dedicated subspecialty in cardiovascular disease prevention. Looking across the United States, one can observe that this is already happening spontaneously through new preventive cardiology and cardiometabolic medicine programs. 8, 36, 39 However, while these secular trends are certainly a step in the right direction, preventive cardiology programs and subspecialty training remain fragmented and unstandardized. Moreover, preventive cardiology is not the sole domain of cardiologists; rather, programs greatly benefit from a broad range of specialists in endocrinology, internal medicine, preventive medicine, family medicine, and obstetrics/gynecology. Regardless of background, a preventive cardiologist of any stripe requires broad expertise in the core competencies of ASCVD risk assessment, lifestyle management, and ASCVD and comorbidity evaluation and treatment. 8, 36 Table 2 provides a list of common referrals to a Center for Preventive Cardiology.

The optimal provision of cardiovascular disease prevention also requires direct integration of other healthcare team members including clinical pharmacists, registered dieticians, genetic counselors, and lifestyle coaches. While pharmacotherapy and other effective interventions are improving, greater emphasis and resources must be allocated to professional-grade lifestyle counseling. In addition, integrating clinical pharmacists into preventive cardiology practice increases both use and adherence to evidence-based preventive medications and markedly reduces patient costs. 40

Dyslipidemia LDL-C, triglycerides, lipoprotein(a) Bempedoic acid, monoclonal antibodies (alirocumab, evolocumab, evinacumab), siRNA (inclisiran), icosapent ethyl, antisense oligonucleotides (APOCIII-LRx, IONIS-APO(a)-LRx) Furthermore, effective models such as the PCSK9 inhibitor clinic highlight the successful integration of clinical pharmacists in preventive cardiology with benefits to patients, medical practice, and healthcare systems. 41, 42 This model needs to be expanded well beyond the application of PCSK9 inhibitors to include the myriad effective, albeit expensive, drugs that are available to mitigate ASCVD risk. Finally, the future of preventive cardiology as a dedicated subspecialty would greatly benefit by integrating the research emerging from the growing number of Centers for Preventive Cardiology. Interesting and/or perplexing cases should be enrolled in collaborative registries and potentially qualify for clinical trials. Prospectively establishing an integrated research network while the field of preventive cardiology is developing could ultimately lead to significant downstream improvements in ASCVD prevention.

We have reached a critical juncture in ASCVD management where US mortality rates are reversing and improvements in intervention of manifest disease are yielding diminishing returns. Furthermore, the growing epidemics of obesity and diabetes stress the importance of a multidimensional approach to managing ASCVD and its risk factors. These disturbing trends call for a paradigm shift from intervention to prevention and have spontaneously led to current efforts to establish a dedicated subspecialty of preventive cardiology. Expertise in preventive cardiology goes well beyond evaluation and management of lipids and requires a distinct, specialized knowledge that spans multiple domains. Fortuitously, we find ourselves at the forefront of an exciting revolution in ASCVD prevention, with an unprecedented number of emerging innovations that vastly enhance ASCVD risk assessment and mitigation. We are just at the beginning, and the future is bright!

• Disturbing trends in cardiovascular risk factors (eg, rising rates of obesity and diabetes) and atherosclerotic cardiovascular disease (ASCVD) mortality (at a nadir and likely rising) in the United States coupled with diminishing returns in treating manifest disease serve as a call to action to focus on cardiovascular disease prevention. • The medical community needs to shift its attention from intervention to multifactorial prevention. • Preventing ASCVD requires multispecialty and multidisciplinary expertise, and this has led to recent efforts to develop the unique subspecialty of preventive cardiology. • We are in the nascent stages of an exciting revolution in ASCVD prevention, with significant advances in risk assessment (eg, subclinical atherosclerosis imaging, novel biomarkers, genetic testing) and emerging targets and novel therapeutics (addressing lipids, diabetes, weight, blood pressure, thrombosis, and inflammation). Table 2 Common referrals to a preventive cardiology center. ASCVD: atherosclerotic cardiovascular disease.

Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association

CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors-United States

Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system

The prevalence of obesity documentation in Primary Care Electronic Medical Records. Are we acknowledging the problem?

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives

Explaining the decrease in U.S. deaths from coronary disease

Functional Trajectories of Persons with Cardiovascular Disease in Late Life

Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics

El Nahas M. Obesity and diabetes in the developing world-a growing challenge

Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis

Centers for Disease Control and Prevention; c2021. Medical Conditions

The Future of Cardiovascular Prevention: Unprecedented Times. Circulation

The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

Prediction of coronary heart disease using risk factor categories

ACC/ AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

The statins in preventive cardiology

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology?

This is an open-access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any noncommercial medium

Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med

Novel biomarkers for cardiovascular risk prediction

Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

Prevention of "Failure": Is It a Failure of Prevention? Circulation

Is Atrial Fibrillation a Preventable Disease?

Cardiometabolic Medicine: A Call for a New Subspeciality Training Track in Internal Medicine

The Role of the Clinical Pharmacist in a Preventive Cardiology Practice

Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities

Application of PCSK9 Inhibitors in Practice